Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Synthetic peptide enhances the microbicidal activity of monocytes

June 16, 2000

Phase I clinical trial begins for Cantab's cervical dysplasia vaccine

June 16, 2000

AdProTech enters collaboration with PowderJect for DNA vaccine program

June 16, 2000

CpG oligodeoxynucleotides for enhancing immune response: NIH offers license

June 16, 2000

Merck presents new inhibitors of Kv1.3 and Kv1.5 channels

June 15, 2000

Novel IK(Ca) channel inhibitor presented at ASBMB/ASPET 2000 by UCI

June 15, 2000

Merck presents two new series of potassium channel blockers for autoimmune diseases, arrhythmias

June 14, 2000

BMS presents new IMP dehydrogenase inhibitors

June 13, 2000

VX-497: in vitro and in vivo findings on a selective, orally active IMPDH inhibitor

June 13, 2000

Health Canada grants priority review to Prevnar

June 13, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.